Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
India's Biocon, Asia's premier biotechnology company, has named Siddharth Mittal as its new chief executive and joint managing director. 3 December 2019
Vancouver, Canada-based regenerative medicine company NervGen Pharma announced the appointment of Paul Brennan as president and chief executive effective immediately. 28 November 2019
Germany-headquartered central nervous system (CNS) specialist Neuraxpharm Group today announced the expansion of its operations in Southern Europe with the launch of Neuraxpharm Portugal. 28 November 2019
The Office of Women’s Health (OWH), part of the US Food and Drug has announced the selection of Kaveeta Vasisht as the Associate Commissioner for Women’s Health. 27 November 2019
Kite Pharma, which was acquired in 2017 by Gilead Sciences in a transaction valued at around $12 billion, announced two new additions to the company’s leadership team. 22 November 2019
Vifor Pharma today announced the appointment of Lee Heeson as president international and a member of the executive committee as of February 1, 2020, with the news sending the Swiss drugmaker’s shares up 2.37% to 161.85 francs. 18 November 2019
A little over five years ago, British drugmaker GlaxoSmithKline was riding high, following multiple years of strong sales and related year-on-year share price gains. 15 November 2019
US healthcare and medical devices company Abbott today announced that Miles White will be stepping down as chief executive on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100, according to the company. 13 November 2019
Shares in Teva Pharmaceutical Industries were up by 11% after 100 minutes of New York trading on Thursday, following the company’s presentation of its third-quarter financial results. 7 November 2019
Swiss specialty drugmaker Santhera Pharmaceuticals this afternoon announced a strategic change to its management team with the appointment of Dario Eklund as chief executive effective December 1, 2019. 4 November 2019
US therapeutic gene editing company Sangamo Therapeutics has appointed Sung Lee as executive vice president and chief financial officer, effective October 31, 2019. Mr Lee oversees finance, facilities and information technology functions for Sangamo and reports to the firm’s chief executive. 2 November 2019
USA-based biotech Ovid Therapeutics has made two senior leadership changes to further build the company’s capabilities as it approaches top-line results from the pivotal Phase III NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. 2 November 2019
Genmab, one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire. 1 November 2019
Shares of UK developer of inhaled therapeutics Vectura Group were up more than 1% at 84.07 pence, after it announced the appointment of Will Downie as chief executive and executive director of the company, effective November 7, 2019. 29 October 2019
Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company, US pharma major Eli Lilly announced today. 23 October 2019
UK biotech start-up Achilles Therapeutics today announced the appointment of Beverley Carr as chief business officer, with effect from November 4, 2019. 21 October 2019
US biotech Gilead Sciences today announced that Andrew Dickinson has been appointed chief financial officer (CFO), effective November 1. 15 October 2019
The Switzerland-based company will be led in its next phase of growth and innovation by an experienced management team and board, with proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries. 9 October 2019
Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ pharma unit to join Ascletis as chief scientific officer. 8 October 2019